[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368367-105":59,"doc-detail-368367-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","surrogate-markers-of-intestinal-dysfunction-associated-with-survival-in-advanced-cancers","Surrogate markers of intestinal dysfunction associated with survival in advanced cancers","","Gut dysbiosis, marked by altered gut microbiota diversity and composition, has been linked to chronic diseases and cancer outcomes, including immunotherapy resistance. Using stool shotgun metagenomics to characterize microbiota ecology and serum MAdCAM-1 to assess endothelial gut barrier dysfunction, the study evaluates survival during chemo-immunotherapy. Across 955 patients in four independent cohorts spanning NSCLC, genitourinary, and colorectal cancers, Akkermansia muciniphila prevalence and MAdCAM-1–related patterns define prognostic strata and reduced-survival subgroups.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/surrogate-markers-of-intestinal-dysfunction-associated-with-survival-in-advanced-cancers/368367/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/surrogate-markers-of-intestinal-dysfunction-associated-with-survival-in-advanced-cancers/368367.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What gut features were investigated as potential survival markers?","Question",{"text":112,"@type":113},"The study assessed gut dysbiosis hallmarks using stool shotgun metagenomics to quantify Akkermansia muciniphila prevalence and used serum MAdCAM-1 to capture endothelial gut barrier dysfunction.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many cancer patients and what cancer types were included?",{"text":117,"@type":113},"The analysis included 955 cancer patients across four independent cohorts, covering non-small cell lung cancer (NSCLC), genitourinary cancers, and colorectal cancer (CRC).",{"name":119,"@type":110,"acceptedAnswer":120},"What combinations were linked to reduced survival in colorectal cancer?",{"text":121,"@type":113},"In CRC, patients with a lack of Akkermansia muciniphila together with low sMAdCAM-1 levels formed a subset with reduced survival, independent of the immunoscore.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368367,1791000106,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","ONCOIMMUNOLOGY  \n2025, VOL. 14, NO. 1, 2484880 [https://doi.org/10.1080/2162402X.2025.2484880](https://doi.org/10.1080/2162402X.2025.2484880)  \nORIGINAL RESEARCH     \nSurrogate markers of intestinal dysfunction associated with survival in advanced cancers  \nRoxanne Birebenta,b,c*, Damien Drubaya,d,e*, Carolina Alves Costa Silvaa,b,c*, Federica Marmorinof,g*, Giacomo Vitalia,c,h, Gianmarco Piccinnoi, Yoan Hurtadoa,b,c, Adele Bonatoa,c,f, Lorenzo Belluominia,c,j, Meriem Messaoudenek,l,  \nBertrand Routyk,l, Marine Fidellea,b,c, Gerard Zalcmanm, Julien Mazieresn, Clarisse Audigier-Valetteo, Denis Moro-Sibilotp, François Goldwasserq,r,s, Arnaud Scherpereelt, Hervé Pegliascou, François Ghiringhelliv,w,x, Anna Renia,c,j,  \nFabrice Barlesia,b,y, Laurence Albigesa,b,y, David Plancharda,b,y, Stéphanie Martinezz, Benjamin Bessea,b,y, Nicola Segatai,aa, Chiara Cremolinif,g*, Laurence Zitvogela,b,c,bb*, Valerio Iebbaa,y*, and Lisa Derosa a,b,c,y*  \naGustave Roussy Cancer Campus, ClinicObiome, Villejuif, France; bFaculté de Medicine, Université Paris-Saclay, Ile-de-France, France; cInstitut National de la Santé et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France; dOffice of Biostatistics and Epidemiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France; eInserm, Université Paris-Saclay, CESP U1018, Oncostat, Villejuif, France; fUnit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy; gDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; hMetaGenoPolis, INRAe, Université Paris-Saclay, Jouy en Josas, France; iDepartment CIBIO, University of Trento, Trento, Italy; jSection of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy; kCentre Hospitalier de l’Université de Montréal (CHUM), Hematology-Oncology Division, Department of Medicine, Montréal, QC, Canada; lCentre de Recherche du CHUM (CRCHUM), Montréal, QC, Canada; mThoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, AP-HP, Université Paris Cité, Paris, France; nService de Pneumologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; oPneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France; pDepartment of Thoracic Oncology, Centre Hospitalier Universitaire, Grenoble, France; qINSERM U1016-CNRS UMR8104-Cochin Institute, Université Paris-Cité, Paris,France; r Department of Medical Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; sImmunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France; tDepartment of Pulmonary and Thoracic Oncology, University of Lille, University Hospital (CHU), INSERM unit OncoThAI, Lille, France; uPulmonary Department, European Hospital, Marseille, France; vCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France; wCentre de Recherche INSERM LNC-UMR1241-CTM (Center of Translational and Molecular Medicine), Dijon, France; x Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France; yDepartment of Clinical Oncology, Gustave Roussy, Villejuif, France; zService des Maladies Respiratoires, Centre Hospitalier d’Aix-en-Provence, Aix-en-Provence, France; aaIEO, European Institute of Oncology IRCCS, Milan, Italy; bbCenter of Clinical Investigations in Biotherapies of Cancer (BIOTHERIS) 1428, Villejuif, France  \nABSTRACT  \nDeviations in the diversity and composition of the gut microbiota are called “gut dysbiosis”. They have been linked to various chronic diseases including cancers and resistance to immunotherapy. Stool shotgun based-metagenomics informs on the ecological composition of the gut microbiota and the prevalence of homeostatic bacteria such as Akkermansia muciniphila (Akk), while determination of the serum addres","cbCaia8wg2qx0rSY","https://ap.wps.com/l/cbCaia8wg2qx0rSY","pdf",4977004,12,"English","# Abstract\n# Introduction\n## Background on immune checkpoint inhibitor biomarkers\n# Keywords","[{\"question\":\"What gut features were investigated as potential survival markers?\",\"answer\":\"The study assessed gut dysbiosis hallmarks using stool shotgun metagenomics to quantify Akkermansia muciniphila prevalence and used serum MAdCAM-1 to capture endothelial gut barrier dysfunction.\"},{\"question\":\"How many cancer patients and what cancer types were included?\",\"answer\":\"The analysis included 955 cancer patients across four independent cohorts, covering non-small cell lung cancer (NSCLC), genitourinary cancers, and colorectal cancer (CRC).\"},{\"question\":\"What combinations were linked to reduced survival in colorectal cancer?\",\"answer\":\"In CRC, patients with a lack of Akkermansia muciniphila together with low sMAdCAM-1 levels formed a subset with reduced survival, independent of the immunoscore.\"}]","Surrogate markers of intestinal dysfunction associated with survival in advanced cancers | PDF",1790176559,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68104bf1d657fd0c1dab55de320b44d5.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bfd17f258526d93d5a74daedb4c892d.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e277804e1d7fe627c0a8ca3dcd278706.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/218e7c0658c10cabcaa4439ccb86b8b9.webp",980,1306]